Insmed Incorporated (NASDAQ:INSM) Receives $44.92 Consensus Target Price from Analysts

Shares of Insmed Incorporated (NASDAQ:INSM) have been assigned a consensus recommendation of “Buy” from the twelve analysts that are currently covering the firm, MarketBeat.com reports. Twelve analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have covered the stock in the last year is $44.92.

INSM has been the subject of a number of analyst reports. Barclays upped their price objective on shares of Insmed from $37.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 11th. StockNews.com downgraded Insmed from a “hold” rating to a “sell” rating in a report on Monday. Guggenheim lifted their price objective on Insmed from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Wells Fargo & Company reiterated an “overweight” rating and set a $55.00 target price on shares of Insmed in a research note on Monday, April 1st. Finally, UBS Group initiated coverage on shares of Insmed in a research note on Tuesday, February 27th. They issued a “buy” rating and a $46.00 price target for the company.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $26.00 on Thursday. The firm has a market capitalization of $3.86 billion, a PE ratio of -4.87 and a beta of 0.93. Insmed has a 12 month low of $18.08 and a 12 month high of $32.00. The business has a 50-day moving average of $26.61 and a two-hundred day moving average of $27.07.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.15). The company had revenue of $83.70 million for the quarter, compared to analysts’ expectations of $82.15 million. The business’s quarterly revenue was up 41.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.20) earnings per share. As a group, research analysts anticipate that Insmed will post -4.65 earnings per share for the current year.

Institutional Investors Weigh In On Insmed

Hedge funds have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC bought a new stake in Insmed during the 4th quarter valued at $25,000. Fidelis Capital Partners LLC bought a new stake in shares of Insmed during the first quarter valued at about $34,000. Headlands Technologies LLC acquired a new stake in Insmed in the first quarter worth about $59,000. China Universal Asset Management Co. Ltd. grew its position in Insmed by 106.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,698 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,910 shares in the last quarter. Finally, Quarry LP acquired a new position in Insmed during the 4th quarter valued at about $116,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.